Immuron (IMRN) Fundamental Analysis: Revenue, Earnings & Valuation

1.68 / 10

Underperform

Fundamentally, Immuron is rated Underperform with a 1.7/10 quality score. Inventory turnover (1.5) and interest coverage (35) are strong, yet revenue growth is high, cost of sales moderate, and current liabilities dominate (95%), indicating financial strain.

Analysis Checks(4/7)

Total operating revenue (YoY growth rate %)

Value48.63

Score1/3

Weight4.60%

1M Return-0.38%

Inventory turnover ratio

Value1.50

Score3/3

Weight11.53%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value95.41

Score0/3

Weight49.62%

1M Return-4.96%

Long-term debt to working capital ratio (%)

Value0.01

Score2/3

Weight4.15%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight13.61%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value48.63

Score1/3

Weight3.61%

1M Return-0.30%

Cost of sales ratio (%)

Value34.61

Score2/3

Weight12.87%

1M Return-1.13%

Is IMRN undervalued or overvalued?

IMRN scores 1.68/10 on fundamentals and holds a Premium valuation at present. Backed by its -18.15% ROE, -62.02% net margin, -2.07 P/E ratio, 0.75 P/B ratio, and 38.63% earnings growth, these metrics solidify its Underperform investment rating.